CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dr Reddy's Laboratories Ltd (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dr Reddy's Laboratories Ltd (Parent)
8-2-337,, Road No.3 Banjara Hills
Phone: +91 4049002900p:+91 4049002900 HYDERABAD, 500034  India Fax: +91 4049002999f:+91 4049002999

Business Summary
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20233/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Kallam S.Reddy 54 1/1/2022
Co-Chairman of the Board, Managing Director Gunupati V.Prasad 61 8/1/2019 4/8/1986
Chief Executive Officer ErezIsraeli 55 8/1/2019 4/2/2018
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.
Aurigene Discovery Technologies Inc.
Aurigene Discovery Technologies Limited
51 additional Business Names available in full report.

General Information
Number of Employees: 14,500 (As of 3/31/2011)
Outstanding Shares: 166,439,200 (As of 9/5/2023)
Shareholders: 74,670
Fax Number: +91 4049002999


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, September 28, 2023